Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (DE:J7Z)
FRANKFURT:J7Z
Holding DE:J7Z?
Track your performance easily
See the Price Targets and Ratings of:
J7Z Analyst Ratings
Strong Buy
15 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
J7Z Stock 12 Month Forecast
Average Price Target
€170.66
▲(46.05% Upside)
| Highest Price Target€221.92 | Average Price Target€170.66 | Lowest Price Target€123.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
Reiterated
12/17/24
TD Cowen
Reiterated
12/17/24
Truist Financial
Assigned
12/13/24
Morgan Stanley
Upgraded
12/12/24
Stifel Nicolaus
Reiterated
12/12/24
Piper Sandler
Reiterated
12/12/24
RBC Capital
Assigned
12/11/24
Jefferies
Reiterated
12/11/24
Leerink Partners
Reiterated
12/11/24
Barclays
Assigned
11/22/24
H.C. Wainwright
€192.97
Buy
65.15%
Upside
Reiterated
11/21/24
Jazz Pharmaceuticals: Promising Growth Potential with Robust Pipeline and Undervalued Market Position
UBS
€116.75→€123.5
Hold
5.69%
Upside
Reiterated
11/19/24
Jazz Pharmaceuticals (JAZZ) PT Raised to $128 at UBSUBS analyst Ashwani Verma raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $128.00 (from $121.00) while maintaining a Neutral rating.
Robert W. Baird
€156.31
Buy
33.77%
Upside
Assigned
11/17/24
Jazz Pharmaceuticals price target raised to $162 from $154 at BairdJazz Pharmaceuticals price target raised to $162 from $154 at Baird
J.P. Morgan
€194.9→€192.97
Buy
65.15%
Upside
Reiterated
11/08/24
J.P. Morgan Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Wells Fargo
€125.43
Hold
7.34%
Upside
Assigned
11/07/24
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (NASDAQ: SLDB), Privia Health Group (NASDAQ: PRVA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Best Analysts Covering Jazz Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy DE:J7Z and Sell After:
1 Month
xxx
Success Rate
20/38 ratings generated profit
Average Return
+0.43%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.63% of your transactions generating a profit, with an average return of +0.43% per trade.
3 Months
xxx
Success Rate
25/41 ratings generated profit
Average Return
+0.13%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.98% of your transactions generating a profit, with an average return of +0.13% per trade.
1 Year
Success Rate
18/26 ratings generated profit
Average Return
+5.73%
reiterated a buy rating 11 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +5.73% per trade.
2 Years
xxx
Success Rate
17/29 ratings generated profit
Average Return
+6.00%
assigned a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 58.62% of your transactions generating a profit, with an average return of +6.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
J7Z Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
22
17
16
17
19
Buy
5
6
9
12
16
Hold
4
5
4
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
28
29
34
39
Each month's total comprises the sum of three months' worth of ratings.
J7Z Financial Forecast
J7Z Stock Forecast FAQ
What is DE:J7Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is €170.66.
What is DE:J7Z’s upside potential, based on the analysts’ average price target?
Jazz Pharmaceuticals has 46.05% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Jazz Pharmaceuticals a Buy, Sell or Hold?
Jazz Pharmaceuticals has a consensus rating of Strong Buy, which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.
What is Jazz Pharmaceuticals’s share price target?
The average share price target for Jazz Pharmaceuticals is €170.66. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €221.92 ,and the lowest forecast is €123.50. The average share price target represents 46.05% Increase from the current price of €116.85.
The highest analyst share price target is €221.92 ,and the lowest forecast is €123.50. The average share price target represents 46.05% Increase from the current price of €116.85.
What do analysts say about Jazz Pharmaceuticals?
Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of Jazz Pharmaceuticals?
To buy shares of DE:J7Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.